Statin use after intracerebral hemorrhage with MRI follow-up
Official title: StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study
Funded at Beth Israel Deaconess Medical Center · NIH-11396134 · Data updated 2026-11-12
This research compares continuing versus stopping statin medicines after lobar intracerebral hemorrhage to see how they affect MRI signs of brain bleeding and small vessel disease in people who were already taking statins.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 15, 2021 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $33,793 |
| NIH project number | 3U01NS120871-02S1 |
| Project ID | NIH-11396134 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with lobar intracerebral hemorrhage who were taking statins at the time of their bleed, can undergo MRI, and can join the parent SATURN trial at a participating site.
✕Less likely to help
People who never took statins, who have non-lobar (deep) ICH, or who cannot have MRI scans are unlikely to qualify or directly benefit from this MRI-focused ancillary study.
What this research studies
If you join, you'll be part of a larger trial where people who had lobar intracerebral hemorrhage and were on statins are randomized to keep taking or stop their statin medicine. You'll get a standardized brain MRI at the start and again at 24 months to look for new cerebral microbleeds or cortical superficial siderosis, which are MRI markers of small vessel disease and bleeding risk. The study compares how often new hemorrhagic MRI markers appear between the two groups and examines whether baseline MRI findings help predict who benefits or is harmed by continuing statins. Your memory, thinking, and functional outcomes may also be followed as part of the parent SATURN trial.
Why it matters
Potential benefit: If successful, results could help doctors decide whether continuing or stopping statins after lobar ICH reduces the risk of future brain bleeds while protecting against heart and blood vessel events.
How similar studies have gone: There are no prior randomized MRI-based trials on this question; existing evidence is limited to observational studies with mixed findings, so this approach is relatively novel.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Selim, Magdy H — Beth Israel Deaconess Medical Center
- Study coordinator: Selim, Magdy H
Related research
Other NIH-funded projects on the same topics.
-
Wearable tech to track blood loss during childbirth
A wearable device monitors cardiovascular signals to detect postpartum hemorrhage early so clinicians can act quickly to protect mothers.
-
SATURN MRI ancillary study: statins after intracerebral hemorrhage and brain MRI markers
This study looks at what happens to brain MRI markers and health outcomes when people with a specific type of brain bleed continue or stop taking statins.
-
Statin use after brain bleed MRI study in ICH patients (SATURN MRI) Ancillary Study
This project tests whether continuing or stopping statin therapy after an intracerebral hemorrhage affects brain changes seen on MRI and related health outcomes in people with lobar ICH.
-
Statin use after brain bleed: SATURN MRI ancillary study
This project tests whether continuing statin medicines after a brain bleed (lobar intracerebral hemorrhage) affects new brain blood vessel findings and long-term health.
-
Maternal Postpartum Monitoring with a Wearable Sensor (MOMS)
A wearable system called MOMS will continuously monitor multiple physiological signals in pregnant people to detect postpartum hemorrhage earlier than standard vital signs.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.